Drug development challenges and strategies to address emerging and resistant fungal pathogens
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Invasive fungal infections represent an expanding threat to public health. The recent emergence of Candida auris, which is often resistant to existing antifungal agents and is associated with a high mortality rate, underscores the urgent need for novel drug development strategies. Areas covered: In this paper, we examine both challenges and opportunities associated with antifungal drug development and explore potential avenues to accelerate the development pipeline, including data sharing, surrogate endpoints, and the role of historical controls in clinical trials. Expert commentary: We review important lessons learned from the study of other rare diseases, including mitochondrial storage diseases and certain forms of cancer that may inform strategies to develop new antifungal agents while highlighting promising new compounds such as SCY-078 for the treatment of invasive fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role and interpretation of pilot studies in clinical research
Leon, A. C., Davis, L. L., & Kraemer, H. C. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.10.008 · Cited by 1,917 · cited 1×
“ential statistics but still demonstrates efficacy and safety (trials of this nature typically have wide confidence intervals) [55].”
BackgroundLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 1×
“agents as well as selection pressure, underscores the need for new therapeutic options and presents unique opportunities [3,96,97].”
BackgroundFirst hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768 · cited 1×
“auris in 2016 was particularly challenging because so little was known about the natural course of disease or the most appropriate method for diagnosis [10,39,40].”
MethodTissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial
Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m13-2508 · Cited by 514
Self-citationLongo, D. L., & Drazen, J. M. (2016) · New England Journal of Medicine · doi:10.1056/nejme1516564 · Cited by 419
Clinical research for rare disease: Opportunities, challenges, and solutions
Griggs, R. C., Batshaw, M., Dunkle, M., Gopal-Srivastava, R., Kaye, E., Krischer, J., Nguyen, T., Paulus, K., & Merkel, P. A. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.10.003 · Cited by 401 · cited 1×
“Fungal disease research poses a number of challenges to clinical investigators (henceforth referred to as ‘trialists’), including the design of clinical studies, funding for clinical research programs, and the discovery, testing, and approval of new treatments [13,14].”
BackgroundWells, K. B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.5 · Cited by 390
Multidrug-Resistant Candida haemulonii and C. auris , Tel Aviv, Israel
Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., Maor, Y., Tarabia, J., Schechner, V., Adler, A., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161486 · Cited by 297
Adaptive trial designs: a review of barriers and opportunities
Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012) · Trials · doi:10.1186/1745-6215-13-145 · Cited by 249
Cited by
Candida auris: a Review of the Literature
Jeffery-Smith, A., Taori, S. K., Schelenz, S., Jeffery, K., Johnson, E. M., Borman, A., Candida auris Incident Management Team, Manuel, R., & Brown, C. S. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-17 · Cited by 595
Fungal diseases as neglected pathogens: A wake-up call to public health officials
Rodrigues, M. L., & Nosanchuk, J. D. (2020) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0007964 · Cited by 342
The Multifunctional Fungal Ergosterol
Rodrigues, M. L. (2018) · mBio · doi:10.1128/mbio.01755-18 · Cited by 275
“million human deaths each year due to systemic mycoses (18), and the currently available therapeutic options are unaffordable, toxic, or inefficient (19).”
BackgroundAntifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
McCarthy, M. W. (2022) · Drugs in R&D · doi:10.1007/s40268-021-00376-x · Cited by 28
Self-citation
Metadata
- Authors
- McCarthy, M. W., & Walsh, T. J.
- Venue
- Expert Review of Anti-infective Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-05-15
- Volume
- 15
- Issue
- 6
- Pages
- 577-584
- ISSN
- 1478-7210 (ISSN-L)
- 1744-8336
- OpenAlex
- W2613139339
- Cited by
- 46
- References
- 16
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug development challenges and strategies to address emerging and resistant fungal pathogens. https://app.cochat.ai/papers/10.1080/14787210.2017.1328279
- The paper
- McCarthy, M. W., & Walsh, T. J. (2017). Drug development challenges and strategies to address emerging and resistant fungal pathogens. Expert Review of Anti-infective Therapy. https://doi.org/10.1080/14787210.2017.1328279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.